LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Kodu・Aktsiate loetelu・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Suletud

SektorTervishoid

12.1 -3.35

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.94

Max

12.54

Põhinäitajad
By Trading Economics
Sissetulek	6.8M -12M
Müük	3.5M 19M
Kasumimarginaal	-64.131
Töötajad	120
EBITDA	7.4M -7.6M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+57.23% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-34M 367M
Eelmine avamishind	15.45
Eelmine sulgemishind	12.1

Uudiste sentiment

By Acuity

26%

74%

82 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

5.04 / 5.44 Toetus ja vastupanu

ENANTA PHARMACEUTICALS INC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. märts 2026, 17:33 UTC

Uudisväärsed sündmused

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27. märts 2026, 17:00 UTC

Uudisväärsed sündmused

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27. märts 2026, 16:03 UTC

Uudisväärsed sündmused

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27. märts 2026, 14:50 UTC

Suurimad hinnamuutused turgudel

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27. märts 2026, 14:37 UTC

Omandamised, ülevõtmised, äriostud

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27. märts 2026, 14:29 UTC

Uudisväärsed sündmused

EU Finance Ministers Tally Economic Hit of Iran War -- Update

27. märts 2026, 14:16 UTC

Uudisväärsed sündmused

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

27. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27. märts 2026, 19:16 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27. märts 2026, 19:07 UTC

Market Talk

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27. märts 2026, 19:04 UTC

Market Talk

Gold Rises But Can't Finish the Week Positive -- Market Talk

27. märts 2026, 19:03 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

27. märts 2026, 19:02 UTC

Market Talk

Uudisväärsed sündmused

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27. märts 2026, 18:12 UTC

Market Talk

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27. märts 2026, 17:36 UTC

Uudisväärsed sündmused

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27. märts 2026, 17:34 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27. märts 2026, 17:29 UTC

Market Talk

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27. märts 2026, 16:38 UTC

Market Talk

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27. märts 2026, 16:32 UTC

Market Talk

Uudisväärsed sündmused

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27. märts 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

27. märts 2026, 15:43 UTC

Market Talk

Uudisväärsed sündmused

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27. märts 2026, 15:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. märts 2026, 15:25 UTC

Market Talk

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27. märts 2026, 15:00 UTC

Uudisväärsed sündmused

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27. märts 2026, 15:00 UTC

Uudisväärsed sündmused

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27. märts 2026, 15:00 UTC

Uudisväärsed sündmused

Fed's Barkin Says Iran War Raising Economic Uncertainty

27. märts 2026, 14:36 UTC

Market Talk

Uudisväärsed sündmused

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27. märts 2026, 14:26 UTC

Market Talk

Uudisväärsed sündmused

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

27. märts 2026, 14:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. märts 2026, 14:14 UTC

Market Talk

Global Energy Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

ENANTA PHARMACEUTICALS INC Prognoos

Hinnasiht

By TipRanks

57.23% tõus

12 kuu keskmine prognoos

Keskmine 19.67 USD 57.23%

Kõrge 20 USD

Madal 19 USD

Põhineb 3 Wall Streeti analüütiku instrumendi ENANTA PHARMACEUTICALS INC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi ENANTA PHARMACEUTICALS INC aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

5.04 / 5.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

82 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.